Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Antioxidant Activity, Molecular Docking, Quantum Studies and In Vivo Antinociceptive Activity of Sulfonamides Derived From Carvacrol

Full text
Author(s):
de Oliveira, Aldo S. [1, 2] ; Llanes, Luana C. [3] ; Nunes, Ricardo J. [4] ; Nucci-Martins, Catharina [5, 6] ; de Souza, Anacleto S. [2] ; Palomino-Salcedo, David L. [2] ; Davila-Rodriguez, Maria J. [7] ; Ferreira, Leonardo L. G. [2] ; Santos, Adair R. S. [6] ; Andricopulo, Adriano D. [2]
Total Authors: 10
Affiliation:
[1] Fed Univ Santa Catarina UFSC, Dept Exact Sci & Educ, Blumenau - Brazil
[2] Univ Sao Paulo, Inst Phys Sao Carlos, Lab Med & Computat Chem, Sao Carlos - Brazil
[3] Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 - USA
[4] Fed Univ Santa Catarina UFSC, Dept Chem, Florianopolis, SC - Brazil
[5] Univ Campinas UNICAMP, Inst Biol, Dept Struct & Funct Biol, Campinas - Brazil
[6] Fed Univ Santa Catarina UFSC, Dept Physiol Sci, Ctr Biol Sci, Florianopolis, SC - Brazil
[7] Fed Univ Sao Carlos UFSCar, Dept Chem, Sao Carlos - Brazil
Total Affiliations: 7
Document type: Journal article
Source: FRONTIERS IN PHARMACOLOGY; v. 12, NOV 23 2021.
Web of Science Citations: 0
Abstract

The synthesis and antioxidant, antinociceptive and antiedematogenic activities of sulfonamides derived from carvacrol-a druglike natural product-are reported. The compounds showed promising antioxidant activity, and sulfonamide derived from morpholine (S1) demonstrated excellent antinociceptive and antiedematogenic activities, with no sedation or motor impairment. The mechanism that underlies the carvacrol and derived sulfonamides' relieving effects on pain has not yet been fully elucidated, however, this study shows that the antinociceptive activity can be partially mediated by the antagonism of glutamatergic signaling. Compound S1 presented promising efficacy and was predicted to have an appropriate medicinal chemistry profile. Thus, derivative S1 is an interesting starting point for the design of new leads for the treatment of pain and associated inflammation and prooxidative conditions. (AU)

FAPESP's process: 13/07600-3 - CIBFar - Center for Innovation in Biodiversity and Drug Discovery
Grantee:Glaucius Oliva
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC